Content about Smoking

CINCINNATI — A new University of Cincinnati study released last week examined how anxiety sensitivity can thwart the efforts of smokers with asthma to quit smoking. This new direction of research from Alison McLeish, a UC assistant professor of psychology, was presented Nov.17 at the 46th annual convention of the Association of Behavioral and Cognitive Therapies in National Harbor, Md.

CHARLOTTE, N.C. – Ballantyne Brands, an electronic cigarette provider, on Monday announced the introduction of a new premium brand, NEO. The company also announced that it has acquired the Mistic brand of electronic cigarettes for an undisclosed amount, and has secured an investment partner to support its business for the long term.

BOSTON — Smokers who have been unsuccessful to date in trying to kick the nicotine habit may be able to stop smoking by combining two smoking cessation approaches, according to a report published in the Oct. 17 issue of JAMA.  

NEW YORK — Global sales of nicotine replacement products are expected to reach $6.2 billion in 2018, following compound annual growth rates of 4.5% between now and then, GBI Research reported Wednesday.

SILVER SPRING, Md. — The Food and Drug Administration has approved a new drug made by Forest Labs for treating chronic obstructive pulmonary disease, the agency said.

The FDA announced the approval of Tudorza Pressair (aclidinium bromide) for the long-term maintenance of COPD-related narrowing of the airways in the lung, also known as bronchospasm. The drug is an inhaled dry powder used twice per day.

Drug Store News recently talked with COPD Foundation founder and president John Walsh about the organization’s new leadership. In March, the COPD Foundation took over leadership for Drive4COPD, which aims to screen people for chronic obstructive pulmonary disease, a collective term for emphysema and chronic bronchitis, which the group estimates to affect 24 million Americans who may have it but don’t know it.


DSN: What led the COPD Foundation to take over Drive4COPD?


Taken together, asthma and chronic obstructive pulmonary disease — which includes chronic bronchitis and emphysema — affect nearly 50 million Americans, or about 15% of the total U.S. population, according to statistics from such organizations as the Centers for Disease Control and Prevention. And combined, the two diseases cause more than 100,000 deaths per year. Fortunately, however, there is a wide range of treatments available for both, many of which work for both diseases.

ATLANTA — Sales of smoking-cessation products may realize a March boom following a recent government advertising campaign that encourages Americans to quit smoking.

One week following the Centers for Disease Control and Prevention's launch of its Tips from Former Smokers campaign, calls to the 1-800-QUIT-NOW quitline were up 130.4%, the agency reported Monday. Calls were up an additional 3.5% in the subsequent week.

A record 34,413 calls were fielded between March 26 and April 1, the CDC reported.

SILVER SPRING, Md. — The Food and Drug Administration on Friday released draft guidance that ultimately will provide the public with previously unknown information about the chemicals in tobacco products and help prevent misleading marketing about the risks associated with tobacco products, the agency said.

PARSIPPANY, N.J. — GlaxoSmithKline Consumer Healthcare strongly supported efforts to inform smokers of the impact tobacco use has on the body, as well as effective ways to quit, during a congressional briefing Friday that was sponsored by Reps. Frank Pallone, D-N.J., and Tim Murphy, R-Pa.

The briefing, entitled "Understanding Smoking Addiction and How to Accelerate Quitting," addressed how to improve the nation's policies and programs to help smokers become tobacco free.

NEW YORK — Regulators will take a few months longer to review the approval application for a new drug for treating chronic obstructive pulmonary disease, the drug's developers said Thursday.

Forest Labs and Almirall said the Food and Drug Administration would require a three-month extension to complete its review of their application for aclidinium bromide, a maintenance drug for COPD. The FDA plans to complete its review and decide whether or not to approve the drug in July.

DEERFIELD, Ill. — Walgreens on Tuesday partnered with Passport Health Plan, a local Medicaid health plan in Louisville, Ky.,  on a new smoking-cessation program that launched in early January. The program is free to Walgreens customers and Passport members and aims to improve the community’s health by giving smokers the tools, resources and ongoing clinical pharmacist counseling to help them achieve their cessation goals.